DHEA and DHEA-S levels in hospitalized adolescents with first-episode schizophrenia and conduct disorder: A comparison study |
| |
| Affiliation: | 1. Beer Yaakov-Ness-Ziona Mental Health Center, Israel;2. Sackler Faculty of Medicine, Tel Aviv University, Israel;3. Geha Mental Health Center, Petah Tikva, Israel;4. Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Beilinson Campus, Petah Tikva, Israel;1. San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA;2. Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Francisco, CA, USA;3. Albert Einstein College of Medicine, New York, NY, USA;4. Northern California Institute for Research and Education, San Francisco, CA, USA;5. Department of Psychiatry, University of California, San Francisco, CA, USA;1. Oklahoma Center for Neuroscience, University of Oklahoma Health Science Center, Oklahoma City, OK, USA;2. Department of Physiology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA;3. VA Medical Center, University of Oklahoma Health Science Center, Oklahoma City, OK, USA;1. Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA;2. Department of Biomedical and Molecular Sciences, Queens University, Kingston, Ontario, Canada;3. University Department of Neurosciences, School of Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA;4. Department of Pediatrics, University of Maryland, School of Medicine, Baltimore, MD, USA;1. Anxiety Disorders Outpatient Program for Children and Adolescents, PROTAIA, Federal University of Rio Grande do Sul, UFRGS/Hospital de Clínicas de Porto Alegre, HCPA, Porto Alegre, Brazil;2. Post Graduate Program in Neuroscience, Institute of Basic Sciences/Health, Federal University of Rio Grande do Sul, UFRGS, Porto Alegre, Brazil;3. Post Graduate Program in Medical Sciences: Psychiatry, Federal University of Rio Grande do Sul, UFRGS, Porto Alegre, Brazil;4. Health Sciences Federal University of Porto Alegre, UFCSPA, Porto Alegre, Brazil;5. Center for Child and Adolescent Health Studies (NESCA), Hospital de Clínicas de Porto Alegre (HCPA), Brazil;6. National Institute of Science and Technology Translational Medicine (INCT/CNPq), Porto Alegre, Brazil;7. Basic Research and Advanced Investigations in Neurosciences, BRAIN Laboratory, Hospital de Clínicas de Porto Alegre, HCPA, Porto Alegre, Brazil;8. Medical Genetics Service, Hospital de Clínicas de Porto Alegre, HCPA, Porto Alegre, Brazil;9. Department of Pediatrics, Faculty of Medicine, UFRGS, Porto Alegre, Brazil;10. National Institute of Developmental Psychiatry for Children and Adolescents (INPD/ CNPq), Brazil;11. Developmental Cognitive Neuroscience Research Group, Post-Graduate Program in Psychology – Human Cognition, Pontifical Catholic University of Rio Grande do Sul, PUCR-RS, Porto Alegre, Brazil;1. Department of Pediatrics, Division Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands;2. Department of Pediatrics, VU University Medical Center, Amsterdam, The Netherlands;3. Department of Pediatric Hemato/Oncology, University Medical Center Utrecht, The Netherlands;4. Department of Pediatric Hemato-Oncology, Radboud University Nijmegen Medical Center, The Netherlands;5. Laboratory of Neuroimmunology and Developmental Origins of Disease (NIDOD), University Medical Center Utrecht, Utrecht, The Netherlands;6. Laboratory of Neuroimmunology of Cancer-related Symptoms (NICRS), University of Texas, MD Anderson Cancer Center, Houston, Texas, USA;7. Department of Pediatrics, Division of Endocrinology, VU University Medical Center, Amsterdam, The Netherlands |
| |
| Abstract: | IntroductionIncreasing evidence exists indicating an association of DHEA and DHEA-S blood levels with psychosis, however many of the findings remain contradictory based on different phases of the illness, different treatments and at a range of ages. To date no studies exist investigating the levels of these neurosteroids in adolescents with psychosis. Such an investigation would be important in order to exclude effects of chronic illness, long-term treatment and repeated hospitalizations.MethodPeripheral venous blood samples for DHEA, DHEA-S and cortisol determination were collected from first-time hospitalized adolescents with diagnoses of schizophrenia as well as from patients with conduct disorder. Patients were rated with the Positive and Negative Syndrome Scale (PANSS), the Hamilton Scale for depression (HAM-D), the Overt Aggression Scale (OAS) and the impulsivity scale (IS).ResultsDHEA levels in adolescents with schizophrenia were significantly higher than in patients with conduct disorder (p = 0.002). Blood levels of DHEA and DHEA-S in schizophrenia correlated with the total PANSS scores (both p < 0.05). No correlations were detected between any of the neurosteroid blood levels and clinical rating scales in the control group.ConclusionsIt may be proposed that individuals in their early stages of schizophrenia psychosis may develop a protective or compensatory neurosteroid response to the first onset of psychosis. Such a putative upregulatory DHEA mechanism may become desensitized with progression to chronic illness. The temporal relationship of investigation of neurosteroid levels in adolescents compared to such investigation in adults may provide important and relevant information. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
